Bupropion and thiothixene versus placebo and thiothixene in the treatment of depression in schizophrenia
- 1 January 1988
- journal article
- research article
- Published by Wiley in Drug Development Research
- Vol. 12 (3-4), 259-266
- https://doi.org/10.1002/ddr.430120308
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Safety and efficacy of bupropion, a novel antidepressantDrug Development Research, 1985
- Bupropion: A new antidepressant drug, the mechanism of action of which is not associated with down-regulation of postsynaptic β-adrenergic, serotonergic (5-HT2), α2-adrenergic, imipramine and dopaminergic receptors in brainNeuropharmacology, 1983
- The lack of effect of bupropion HCL (Wellbatrin) on the secretion of growth hormone and prolactin in humansLife Sciences, 1982
- Some neurochemical properties of a new antidepressant, bupropion hydrochloride (Wellbutrin™)Drug Development Research, 1981
- Influence of bupropion HCL (Wellbatrin®), a novel antidepressant, on plasma levels of prolactin and growth hormone in man and ratLife Sciences, 1979
- Use of Antidepressant Drugs in SchizophreniaArchives of General Psychiatry, 1978
- 'Akinetic Depression' in SchizophreniaArchives of General Psychiatry, 1978
- Trials of Lithium, Chlorpromazine and Amitriptyline in Schizoaffective PatientsThe British Journal of Psychiatry, 1978
- A Controlled Trial of Amantadine in Drug-Induced Extrapyramidal DisordersArchives of General Psychiatry, 1976
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960